Stock comparison
Align Technology
Halozyme Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ALGN
Align Technology
Market cap
$11.81B
Sector
Healthcare
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ALGN | HALO | Winner |
|---|---|---|---|
| Warren Buffett | 56C | 79B | HALO |
| Benjamin Graham | 66B | 83A | HALO |
| Philip Fisher | 40D | 65B | HALO |
| Peter Lynch | 18F | 53D | HALO |
| Joel Greenblatt | 36D | 40D | HALO |
| Charlie Munger | 42D | 80C | HALO |
| Terry Smith | 44D | 84A | HALO |
Side-by-side metrics
| Metric | ALGN | HALO |
|---|---|---|
| Market cap | $11.81B | $8.1B |
| P/E (TTM) | 26.1x | 24.0x |
| EV/EBIT | 16.7x | 10.2x |
| ROIC (TTM) | 9.72% | 23.65% |
| Gross margin | 67.68% | 81.24% |
| Net margin | 10.5% | 23.13% |
| Revenue CAGR 5y | 0.52% | 33.23% |
| EPS CAGR 5y | -12.78% | -1.98% |
| Debt / Equity | 0.0x | 1.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ALGN leads on
- Debt / Equity0.0xvs 1.0x+98%
- Market cap$11.81Bvs $8.1B+31%
HALO leads on
- Revenue CAGR 5y33.23%vs 0.52%+98%
- EPS CAGR 5y-1.98%vs -12.78%+84%
- ROIC (TTM)23.65%vs 9.72%+59%
- Net margin23.13%vs 10.5%+55%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.